

A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI

1. Introduction

Sponsors, Research Bases, and the Investigator

2. The Sponsor	2
2.1 How NCI Funds Research	3
2.2 Preclinical Development of New Agents	3
2.3 Collaboration Between Sponsors: DCTD and the Pharmaceutical Companies	3
2.4 Private Support of Trials Sponsored and Funded by NCI	4
2.5 Private Support of Trials Sponsored but Not Funded by NCI	4
2.6 The Investigational New Drug Application (IND)	4
2.7 The Marketing Application	5
3. The Research Base and the Investigator	6
3.1 Definition and Purpose of a Research Base for Clinical Trials	6
3.2 Activities of the Research Base	6
3.2.1 Protocol Development	6
3.2.1.1 Scientific Review	6
3.2.1.2 Biostatistical Consultation	7
3.2.2 Protocol Administration	7
3.2.3 Establishment of an Affiliate Program	7
3.2.4 Agent Accountability and Storage	7
3.2.5 Reporting of Results to CTEP	7
3.2.6 Data Management and Statistics	7
3.2.7 Quality Assurance	8

The Development of a Clinical Trial

4. Phase 1 Trials	9
4.1 Scientific Policies of CTEP	9
4.1.1 Planning of Phase 1 Trials	9
4.1.2 Objectives	9
4.1.3 Patient Selection	9
4.1.4 Schedule Selection	9
4.1.5 Starting Dose	10
4.1.6 Dose Escalation	10
4.1.7 Pharmacokinetics	10
4.2 Who Is Eligible to Study Phase 1 Agents	10
4.2.1 Contractors	10
4.2.2 Other Phase 1 Investigators	11
4.3 Which Organizations Can Conduct Phase 1 Studies	11
4.4 Who Is Eligible to Administer Phase 1 Agents	11
4.5 How to Obtain Information About Phase 1 Agents	11
4.5.1 Investigator's Brochure	11
4.5.2 IDB Physicians	11
4.5.3 Other Information	11

5. Phase 2 Trials	12
5.1 Scientific Policies of CTEP	12
5.1.1 New Agent Development Considerations	12
5.1.1.1 Planning and Coordination of Phase 2 Trials by CTEP	12
5.1.1.2 Single Agent Phase 2 Studies	12
5.1.1.3 Combining Agents	13
5.1.2 Individual Protocol Considerations	14
5.1.2.1 Single Disease Studies	14
5.1.2.2 Eligibility Requirements	14
5.1.2.3 Accrual and Statistical Considerations	15
5.2 Who is Eligible to Study Phase 2 Agents	15
5.2.1 Cooperative Groups	15
5.2.2 Cancer Centers	15
5.2.3 Affiliates	16
5.2.4 New Agent Development Contractors and Cooperative Agreement and Awardees	16
5.2.5 Multicenter Phase 2 Trials	16
5.3 Who is Eligible to Administer Phase 2 Agents	16
5.4 Restriction on Participation in Phase 2 Studies	16
5.5 How to Obtain Information About Phase 2 Agents	16
5.5.1 Investigator's Brochure	16
5.5.2 IDB Physicians	17
5.5.3 Clinical Research Pharmacists	17
5.6 The Letter of Intent	17
5.6.1 Definition	17
5.6.2 Purpose	17
5.6.3 Ground Rules for the LOI System	17
5.6.4 Submission of LOIs	18
5.6.5 Review of LOIs	18
5.6.6 CTEP LOI Review Criteria	18
5.6.7 After LOI Approval	19
5.6.8 Information About the Status of an LOI	19
6. Phase 3 Trials	19
6.1 Scientific Policies of CTEP	19
6.2 Who Is Eligible to Conduct Phase 3 Trials	20
6.3 Eligibility Requirements	20
6.4 Coordination of Planning With CTEP Staff	21
The Planning and Execution of a Clinical Trial	
7. The Drafting of a Protocol	21
7.1 Title Page	22
7.2.1 Schema	22
7.2.2 Objective(s)	22
7.2.3 Background and Rationale	22
7.2.4 Patient Eligibility Criteria	22

7.2.5 Pharmaceutical Information	23
7.2.5.1 Investigational Agent Pharmaceutical Section	23
7.2.5.2 Commercial Agent Pharmaceutical Section	23
7.2.6 Treatment Plan	23
7.2.7 Procedures for Patient Entry on Study	24
7.2.8 Dose Modification for Adverse Events	24
7.2.9 Criteria for Response Assessment	24
7.2.10 Monitoring of Patients	24
7.2.11 "Off-Study" Criteria	24
7.2.12 Statistical Considerations	24
7.2.13 Records to be Kept	25
7.2.14 Participation	25
7.2.15 Multicenter Trials	25
7.2.16 Laboratory Approaches to be Used for Ancillary Studies	26
7.3 Informed Consent	26
7.4 Protocol Templates	27
7.5 Protocol Checklist	27
 8. Protocol Review and Approval at CTEP	 27
8.1 The Protocol and Information Office (PIO)	27
8.2 How to Submit a Protocol	27
8.3 IRB Approval	27
8.4 Protocol Review	28
8.4.1 Receipt of the Protocol by CTEP	30
8.4.2 Scheduling the Protocol for Review	31
8.4.3 Review by the CTEP Protocol Review Committee	31
8.4.3.1 The Review of the Protocol	31
8.4.3.2 The Review of the Informed Consent	31
8.4.3.3 The Review of Regulatory and Administrative Concerns	32
8.4.3.4 The Consensus Review	32
8.4.3.5 Responding to CTEP Consensus Review	32
8.5 Protocol Approval	32
8.6 Amendments	32
8.6.1 Editorial Amendments	33
8.6.2 Activation Amendment	33
8.6.3 Scientific and Participant Amendments	33
8.7 Study Status	
8.8 Reactivation of Studies	34
 9. Ordering Investigational Agents from NCI	 34
9.1 How to Place Agent Orders	34
9.2 Particular Points to Note	35
9.3 Routing of Agent Requests	35
9.4 Affiliates and Agent Orders	35
9.5 Requests for Nonresearch (Treatment) Use of Investigational Agents	36
9.6 Requests for Nonclinical (Laboratory) Use of Investigational Agents	36

9.7 Status of Investigational Agents Following FDA Marketing Approval	36
10. Responsibility for Reporting Results to CTEP	36
10.1 Introduction	37
10.2 Report Requirements of Phase 1, 2 and 3 Trials	37
10.2.1 Clinical Trials Monitoring Service (CTMS)	37
10.2.2 Clinical Data Update System	38
10.2.3 Adverse Events	39
10.2.4 Study Status	39
10.2.5 Amendments	39
10.2.6 Presentations	40
10.2.7 Publications	40
10.3 Retention of Records	40
10.4 Reporting to IRBs	40
11. Adverse Events	40
11.1 Adverse Events with Commercially Available (Non-Investigational) Agents	41
11.2 Adverse Events and Routine Reporting of Adverse Events	41
11.3 Actions Taken by CTEP on AE Reports	41
The Organization of a Clinical Trial	
12. The Investigator and Protocol Chair: Roles and Responsibilities	41
12.1 The Investigator	42
12.1.1 The FDA Form 1572	42
12.1.2 Responsibilities of an Investigator for Human Subjects Protection	42
12.2 The Protocol Chair	43
12.2.1 Responsibilities	43
12.2.2 Who May Serve as a Protocol Chair	43
13. Affiliate Investigators	43
13.1 Affiliate Investigators Definition	44
13.2 Requirements of an Affiliate Investigator	44
13.3 Responsibilities of Affiliate Investigators	44
13.4 Responsibilities of Research Bases for Affiliates	44
13.4.1 The Cooperative Groups	44
13.4.2 The Principal Investigator Responsibilities for Affiliate Investigators in Cooperative Group Protocols	45
13.4.3 Cancer Centers	45
14. Who May Administer Investigational Agents	45
14.1 Restrictions to Physicians Registered as Investigators with CTEP	45
15. Accountability and Storage of Investigational Agents	46
15.1 Procedures for Agent Accountability and Storage	46
15.2 Investigational Agent Returns	47
15.3 Verification of Compliance	47

15.4 Handling of Antineoplastic Agents	48
16. Monitoring and Quality Assurance	48
16.1 Introduction	48
16.2 Protocol Compliance	49
16.2.1 Cooperative Groups	49
16.2.2 Cancer Centers	49
16.2.3 CTEP Clinical Agent Development Contractors	49
16.3 Data Accuracy	49
16.4 Procedural Requirements	49
16.5 Components of the Quality Assurance Program Implemented by CTEP	50
16.5.1 Monitoring	50
16.5.2 The On-Site Auditing Program	50
16.5.2.1 Purpose of Site Visit Audits	50
16.5.2.2 Outline of Audit Procedures	50
16.5.2.3 Adaptations of Basic Procedures to Specific Needs	51
16.6 Informed Consent and the Monitoring Program	51
16.7 Dealing with Problems Identified During On-Site Audits	52
Nonresearch or Treatment Referral Protocol Use of Investigational Agents	
17. Group C	52
17.1 Definition	52
17.2 Placement of an Agent in Group C	53
17.3 Current Group C Agents	53
17.4 Use of a Group C Agent	53
17.5 Requesting a Group C Agent	53
17.6 Responsibilities When Using Group C Agents	53
18. Special Exceptions	54
18.1 Definition	54
18.2 Criteria for Approval of a Special Exception Request	54
18.3 Requesting a Special Exception Agent	55
18.4 Responsibilities of Physicians Administering Special Exception Agents	55
19. Treatment Referral Center (TRC)	55
19.1 Purpose	55
19.2 Method	55
19.3 Access to the TRC	55

Appendices

Appendix I – NCI-Cooperative Group-Industry Relationship Guidelines	1
Appendix II – Special Article: Commentary Concerning Demonstration of Safety and Efficacy of Investigational Anticancer Agents in Clinical Trials	1
Appendix III – Policy Statement: The Conduct of Phase 1 Trials in Children	10
Appendix IV – Key Contact Addresses and Telephone Numbers	14
Appendix V – Instructions for Completing Statement of Investigator (FDA 1572 Form), Supplemental Investigator Data Form, and Financial Disclosure Form	16
Appendix VI – Guidelines for Submitting Letter of Intent and Completing Letter of Intent Forms	16
Appendix VII – Informed Consent Checklist	17
Appendix VIII – Protocol Submission Worksheet	19
Appendix IX – CTEP Glossary	19
Appendix X – Clinical Drug Request (NIH-986)	22
Appendix XI – Adverse Event Expedited Reporting System (AdEERS)	22
Appendix XII – NCI Investigational Drug Accountability Record Form	22
Appendix XIII – National Study Commission on Cytotoxic Exposure: Recommendations for Handling Cytotoxic Agents	22
Appendix XIV – Policy for Group C Drug Distribution	27
Appendix XV – National Cancer Institute Procedure of Investigational Drugs Acquired for Compassionate (Special Exception) Treatment of Individual Patients	30
Appendix XVI – Guidelines for Treatment Regimens EXPRESSION AND NOMENCLATURE	34
Appendix XVII – Status of the NCI Preclinical Antitumor Agent Discovery Screen, Principles and Practice of Oncology Updates	39